Factors related to Health-Related Quality of Life (HRQoL) among children with ADHD in Europe at entry into treatment

Riley, Anne W.; Spiel, Georg; Coghill, David; Döpfner, Manfred; Falissard, Bruno; Lorenzo, Maria J.; Preuss, Ulrich W.; Ralston, S

doi:10.1007/s00787-006-1006-9

Cited by 127 publications

(114 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first thing we can conclude from these findings is that the test-metrical qualities of the instrument we devised (the ILK) render it usable and capable of holding its own among other, comparable instruments Riley et al 2006b). Our study has three special properties: First, it was carried out on an unselected group of patients who presented consecutively, without gaps, to 9 outpatient practices for child and adolescent psychiatry.…”

Section: Discussionmentioning

confidence: 94%

“…In a further study published in the same Supplement (Riley et al 2006b), the authors determined the factors that were associated with the patients' health-related quality of life (HRQoL). In addition to the hallmark manifestations of ADHD, these factors included conduct disturbances, problems with peer relationships, bronchial asthma, a variety of other bodily symptoms, and impaired motor coordination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The quality of life of children and adolescents with ADHD undergoing outpatient psychiatric treatment: simple disorders of activity and attention and hyperkinetic conduct disorders in comparison with each other and with other diagnostic groups

Remschmidt

Mattejat

2010

ADHD Atten Def Hyp Disord

View full text Add to dashboard Cite

(1) How does the quality of life of patients with ADHD treated in an ambulatory care setting compare to that of other patient groups in child and adolescent psychiatry? (2) Can differences in the quality of life be demonstrated between patients with simple disorders of activity and attention and those with hyperkinetic conduct disorders? (3) How does the quality of life in these patient groups change over one year of treatment? The Inventory for the Assessment of Life Quality in Children and Adolescents (Inventar zur Untersuchung der Lebensqualität von Kindern und Jugendlichen, ILK) was applied to a sample of 726 patients derived from nine different outpatient practices for child and adolescent psychiatry. Among them were 196 patients with a simple disorder of activity and attention and 64 with a hyperkinetic conduct disorder. A comparison between these two groups was the main aim of the study. The mean age of the patients in the sample (all diagnoses) was 8.7 ± 3 years. The two groups of hyperkinetic patients made up 35% of the overall sample, and both of them showed a marked male predominance. The hyperkinetic patients tended to have lower quality-of-life scores than patients in the other diagnostic groups. Longitudinal observation revealed improvements in the quality of life across all patient groups, but the patients with hyperkinetic disorders (both groups) improved the least. The parents of the hyperkinetic patients, too, reported suffering greater stress because of their children's condition than the parents of children with other types of disorders. The ILK instrument has test-metrical qualities that render it usable and capable of holding its own among other, comparable instruments. It can be used to assess the quality of life of children with various diagnoses. Children with ADHD tend to have the least favorable quality-of-life scores, yet they do show some degree of improvement in their quality of life after a year of treatment.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

The quality of life of children and adolescents with ADHD undergoing outpatient psychiatric treatment: simple disorders of activity and attention and hyperkinetic conduct disorders in comparison with each other and with other diagnostic groups

Remschmidt

Mattejat

2010

ADHD Atten Def Hyp Disord

View full text Add to dashboard Cite

show abstract

“…ADHD is characterized by inattention, hyperactivity and impulsivity, and associated with social, academic and mental health issues [3][4][5]. ADHD with a heritability of approximately 0.8 [6][7][8] is associated with obesity [9][10][11][12][13], smoking [14,15], psychiatric comorbidities [16] and poor health in general [17].…”

Section: Introductionmentioning

confidence: 99%

Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Antel

Albayrak

Heusch³

et al. 2014

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

With the recent approval of methylphenidate (MPH) for treating attention-deficit/hyperactivity disorder (ADHD) in adults, the number of patients exposed will increase tremendously. The ongoing debate on the cardiovascular safety of MPH has triggered two large retrospective cohort studies in children and adolescents as well as in young to middle-aged adults. These studies looked into serious cardiovascular events (sudden cardiac death, acute myocardial infarction and stroke) as primary endpoints and concluded that MPH was safe after a mean duration of 2.1 years of follow-up in children and adolescents and mean duration of 0.33 years of current use in adults. The results are encouraging with respect to the short- and medium-term use of MPH. Without the inherent limitations of retrospective cohort studies, a prospective randomized, double-blind, placebo-controlled, multicenter trial in individuals stratified for cardiovascular risk factors would allow for an optimized risk assessment. With many millions of patients treated per year and drawing parallels to the lately discovered risks of sibutramine, another sympathomimetic with an overlapping mode of action and similar side effects on heart rate and blood pressure, we hypothesize that such a trial might be a dedicated risk mitigation strategy for public health. A critical assessment of cardiovascular side effects of MPH appears particularly warranted, because ADHD is associated with obesity, smoking and poor health in general. We summarize recent findings with the focus on cardiovascular risks of MPH in humans; we additionally analyze the limited number of rodent studies that have addressed cardiovascular risks of MPH.

show abstract

“…ADHD is associated with a significant impairment of psychosocial functioning that may affect the quality of life (QoL) [2][3][4][5][6][7][8][9][10]. ADHD is accompanied by comorbid oppositional defiant disorder (ODD) or conduct disorder (CD) in 40-60% of pediatric ADHD patients [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder

et al. 2010

View full text Add to dashboard Cite

show abstract

Factors related to Health-Related Quality of Life (HRQoL) among children with ADHD in Europe at entry into treatment

Abstract: Numerous factors independently impact on the HRQoL of children with ADHD.

Cited by 127 publications

References 23 publications

The quality of life of children and adolescents with ADHD undergoing outpatient psychiatric treatment: simple disorders of activity and attention and hyperkinetic conduct disorders in comparison with each other and with other diagnostic groups

The quality of life of children and adolescents with ADHD undergoing outpatient psychiatric treatment: simple disorders of activity and attention and hyperkinetic conduct disorders in comparison with each other and with other diagnostic groups

Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder

Contact Info

Product

Resources

About